The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Background: Resistant bipolar disorder is a major mental health problem related to significant disability and overall cost. The aim of the current study was to perform a systematic review of the literature concerning (1) the definition of treatment resistance in bipolar disorder, (2) its clinical and (3) neurobiological correlates, and (4) the evidence-based treatment options for treatment-resistant bipolar disorder and for eventually developing guidelines for the treatment of this condition Materials and Methods: The PRISMA method was used to identify all published papers relevant to the definition of treatment resistance in bipolar disorder and the associated evidence-based treatment options. The MEDLINE was searched to April 22, 2018. Results: Criteria were developed for the identification of resistance in bipolar disorder concerning all phases. The search of the literature identified all published studies concerning treatment options. The data were classified according to strength, and separate guidelines regarding resistant acute mania, acute bipolar depression, and the maintenance phase were developed. Discussion: The definition of resistance in bipolar disorder is by itself difficult due to the complexity of the clinical picture, course, and treatment options. The current guidelines are the first, to our knowledge, developed specifically for the treatment of resistant bipolar disorder patients, and they also include an operationalized definition of treatment resistance. They were based on a thorough and deep search of the literature and utilize as much as possible an evidence-based approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative
Merikangas, K. R., Jin, R., He, J.-P., Kessler, R. C., Lee, S., Sampson, N. A., Viana, M. C., Andrade, L. H., Hu, C., Karam, E. G., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.12 · Cited by 2,627
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationGrande, I., Berk, M., Birmaher, B., & Vieta, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00241-x · Cited by 1,710
Self-citationBerk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 1×
“Response to a single ketamine infusion may appear within hours but does not last more than 3 to 4 days (Diazgranados et al., 2010; Zarate et al., 2012; Lally et al., 2014; Loebel et al., 2014; Xu et al., 2015).”
BackgroundVieta, E., Berk, M., Schulze, T. G., Carvalho, A. F., Suppes, T., Calabrese, J. R., Gao, K., Miskowiak, K. W., & Grande, I. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.8 · Cited by 891
Self-citationOmega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K., & Marangell, L. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.407 · Cited by 814
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 1×
“Repeated administration of ketamine studies have not been carried in BD (Murrough et al., 2013; Phillips et al., 2019).”
BackgroundHopewell, S., Clarke, M., Moher, D., Wager, E., Middleton, P., Altman, D. G., Schulz, K. F., & and the CONSORT Group (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050020 · Cited by 674
Research works printed but not linked: 282
- Abdallah, 2012, Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting, J ECT, 28, 157, 10.1097/YCT.0b013e31824f8296 · DOI
- Altshuler, 1999, Gabapentin in the acute treatment of refractory bipolar disorder, Bipolar Disord, 1, 61, 10.1034/j.1399-5618.1999.10113.x · DOI · Paper page
- Altshuler, 2009, Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study, J Clin Psychiatry, 70, 450, 10.4088/JCP.08m04191 · DOI · Paper page
- Amann, 2007, A 2-year, open-label pilot study of adjunctive chromium in patients with treatment-resistant rapid-cycling bipolar disorder, J Clin Psychopharmacol, 27, 104, 10.1097/JCP.0b013e31802e744b · doi:10.1097/jcp.0b013e31802e744b
- American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders 4th Edition, Text Revision, DSM-IV-TR
- Amsterdam, 2016, Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression, Bipolar Disord, 18, 563, 10.1111/bdi.12442 · DOI
- Amsterdam, 2016, Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate, Br J Psychiatry, 208, 359, 10.1192/bjp.bp.115.169375 · DOI · Paper page
- Anand, 2012, Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial, Bipolar Disord, 14, 64, 10.1111/j.1399-5618.2011.00971.x · DOI · Paper page
- Aronson, 1989, Clonazepam treatment of five lithium-refractory patients with bipolar disorder, Am J Psychiatry, 146, 77, 10.1176/ajp.146.1.77 · DOI
- Baek, 2014, Pattern of pharmacotherapy by episode types for patients with bipolar disorders and its concordance with treatment guidelines, J Clin Psychopharmacol, 34, 577, 10.1097/JCP.0000000000000175 · DOI
- Ball, 2006, A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change, J Clin Psychiatry, 67, 277, 10.4088/JCP.v67n0215 · DOI · Paper page
- Barton, 1987, Verapamil in treatment-resistant mania: an open trial, J Clin Psychopharmacol, 7, 101, 10.1097/00004714-198704000-00011 · DOI
- Bauer, 2017, The Link between refractoriness and neuroprogression in treatment-resistant bipolar disorder, Mod Trends Pharmacopsychiatry, 31, 10, 10.1159/000470803 · DOI
- Bauer, 1994, Refractoriness induced by lithium discontinuation despite adequate serum lithium levels, Am J Psychiatry, 151, 1522, 10.1176/ajp.151.10.1522 · DOI
- Bauer, 1999, Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study, J Clin Psychopharmacol, 19, 164, 10.1097/00004714-199904000-00012 · DOI · Paper page
- Bauer, 2002, Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders, Neuropsychopharmacology, 27, 620
- Bauer, 2016, Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study, Mol Psychiatry, 21, 229, 10.1038/mp.2014.186 · DOI
- Bauer, 1990, Rapid cycling bipolar affective disorder, Archives of General Psychiatry, 47, 435, 10.1001/archpsyc.1990.01810170035006 · DOI · Paper page
- Bauer, 1990, Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study, Arch Gen Psychiatry, 47, 435, 10.1001/archpsyc.1990.01810170035006 · DOI · Paper page
- Behzadi, 2009, Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial, Acta Psychiatr Scand, 120, 441, 10.1111/j.1600-0447.2009.01368.x · DOI
- Benedetti, 2010, Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study, Clinical practice and epidemiology in mental health: CP & EMH, 6, 30, 10.2174/1745017901006010030 · doi:10.2174/1745017901006010030
- Berk, 2011, Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention, Bipolar Disord, 13, 87, 10.1111/j.1399-5618.2011.00889.x · DOI · Paper page
- Berk, 2019, A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo, BMC Med, 17, 18, 10.1186/s12916-019-1257-1 · DOI · Paper page
- Berk, 2019, Correction to: a randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo, BMC Med, 17, 35, 10.1186/s12916-019-1280-2 · DOI
- Bersudsky, 2010, Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial, Bipolar Disord, 12, 376, 10.1111/j.1399-5618.2010.00828.x · DOI
- Berwaerts, 2011, Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study, J Affect Disord, 129, 252, 10.1016/j.jad.2010.09.011 · DOI
- Bjørklund, 2016, Trends in the psychopharmacological treatment of bipolar disorder: a nationwide register-based study, Acta Neuropsychiatr, 28, 75, 10.1017/neu.2015.52 · DOI
- Bobo, 2010, Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder, Expert Rev Neurother, 10, 1637, 10.1586/ern.10.143 · DOI · Paper page
- Bobo, 2016, Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice, Depress Anxiety, 33, 698, 10.1002/da.22505 · DOI
- Bocchetta, 1993, A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives, Acta Psychiatr Scand, 88, 434, 10.1111/j.1600-0447.1993.tb03487.x · DOI · Paper page
- Bowden, 1999, The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder, Biol Psychiatry, 45, 953, 10.1016/S0006-3223(99)00013-X · DOI
- Burdick, 2012, Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction, J Clin Psychiatry, 73, 103, 10.4088/JCP.11m07299 · DOI
- Caddy, 2014, Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy, Ther Adv Psychopharmacol, 4, 75, 10.1177/2045125313507739 · DOI
- Calabrese, 1996, Clozapine for treatment-refractory mania, Am J Psychiatry, 153, 759, 10.1176/ajp.153.6.759 · DOI · Paper page
- Calabrese, 1999, Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder, Am J Psychiatry, 156, 1019, 10.1176/ajp.156.7.1019 · DOI · Paper page
- Calabrese, 2001, A pilot study of topiramate as monotherapy in the treatment of acute mania, J Clin Psychopharmacol, 21, 340, 10.1097/00004714-200106000-00015 · DOI
- Calabrese, 2010, Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study, J Clin Psychiatry, 71, 1363, 10.4088/JCP.09m05900gry · DOI
- Calabrese, 2014, Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial, J Clin Psychiatry, 75, 1054, 10.4088/JCP.13m08951 · DOI
- Cardoso, 2015, Biological rhythm and bipolar disorder: twelve-month follow-up of a randomized clinical trial, J Nerv Ment Dis, 203, 792, 10.1097/NMD.0000000000000369 · DOI
- Chen, 2011, Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study, Hum Psychopharmacol, 26, 588, 10.1002/hup.1249 · DOI
- Chen, 2013, A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania, Neuropsychiatr Dis Treat, 9, 839, 10.2147/NDT.S40503 · DOI
- Chengappa, 1999, Topiramate as add-on treatment for patients with bipolar mania, Bipolar Disord, 1, 42, 10.1034/j.1399-5618.1999.10111.x · DOI
- Chengappa, 2000, Inositol as an add-on treatment for bipolar depression, Bipolar Disord, 2, 47, 10.1034/j.1399-5618.2000.020107.x · DOI
- Chiu, 2005, Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder, J Clin Psychiatry, 66, 1613, 10.4088/JCP.v66n1219b · DOI · Paper page
- Ciapparelli, 2000, Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study, J Clin Psychiatry, 61, 329, 10.4088/JCP.v61n0502 · DOI
- Ciapparelli, 2003, Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study, J Clin Psychiatry, 64, 451, 10.4088/JCP.v64n0416 · DOI
- Ciappolino, 2017, The role of n-3 polyunsaturated fatty acids (n-3PUFAs) in affective disorders, J Affect Disord, 224, 32, 10.1016/j.jad.2016.12.034 · DOI
- Citrome, 2010, Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults, Expert Rev Neurother, 10, 1031, 10.1586/ern.10.66 · DOI
- Cole, 1993, Patterns of treatment resistance in bipolar affective disorder, Acta Psychiatr Scand, 88, 121, 10.1111/j.1600-0447.1993.tb03424.x · DOI
- Colom, 2003, A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission, Arch Gen Psychiatry, 60, 402, 10.1001/archpsyc.60.4.402 · DOI · Paper page
- Colom, 2009, Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial, Br J Psychiatry, 194, 260, 10.1192/bjp.bp.107.040485 · DOI · Paper page
- Colom, 2010, Has number of previous episodes any effect on response to group psychoeducation in bipolar patients? A 5-year follow-up post hoc analysis, Acta Neuropsychiatr, 22, 50, 10.1111/j.1601-5215.2010.00450.x · DOI
- da Costa, 2016, Refractory bipolar disorder and neuroprogression, Prog Neuropsychopharmacol Biol Psychiatry, 70, 103, 10.1016/j.pnpbp.2015.09.005 · DOI
- Dauphinais, 2012, Controlled trial of safety and efficacy of bright light therapy vs. negative air ions in patients with bipolar depression, Psychiatry Res, 196, 57, 10.1016/j.psychres.2012.01.015 · DOI · Paper page
- de Barros Pellegrinelli, 2013, Efficacy of psychoeducation on symptomatic and functional recovery in bipolar disorder, Acta Psychiatr Scand, 127, 153, 10.1111/acps.12007 · DOI · Paper page
- De Beaurepaire, 1992, Treatment of neuroleptic-resistant mania and schizoaffective disorders, Am J Psychiatry, 149, 1614, 10.1176/ajp.149.11.1614 · doi:10.1176/ajp.149.11.1614
- Dell’Osso, 2013, Assessing efficacy/effectiveness and safety/tolerability profiles of adjunctive pramipexole in bipolar depression: acute versus long-term data, Int Clin Psychopharmacol, 28, 297, 10.1097/YIC.0b013e3283639015 · DOI
- Dell’Osso, 2009, Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression, Bipolar Disord, 11, 76, 10.1111/j.1399-5618.2008.00651.x · DOI
- Denicoff, 1997, Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder, Am J Psychiatry, 154, 1456, 10.1176/ajp.154.10.1456 · DOI
- D’Urso, 2017, Clinical predictors of acute response to transcranial direct current stimulation (tDCS) in major depression, J Affect Disord, 219, 25, 10.1016/j.jad.2017.05.019 · DOI
- Eden Evins, 2006, A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania, Bipolar Disord, 8, 75, 10.1111/j.1399-5618.2006.00243.x · DOI
- Erfurth, 2002, Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients, Neuropsychobiology, 45 (Suppl 1), 33, 10.1159/000049259 · DOI
- Esan, 2017, Bipolar I disorder in remission vs. schizophrenia in remission: is there a difference in burden?, Compr Psychiatry, 72, 130, 10.1016/j.comppsych.2016.10.009 · DOI
- Fan, 2012, Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study, Bipolar Disord, 14, 206, 10.1111/j.1399-5618.2012.01001.x · DOI
- Fitzgerald, 2016, A negative double-blind controlled trial of sequential bilateral rTMS in the treatment of bipolar depression, J Affect Disord, 198, 158, 10.1016/j.jad.2016.03.052 · DOI
- Fond, 2014, Ketamine’s effectiveness in unipolar versus bipolar depression, Psychopharmacology (Berl), 231, 4417, 10.1007/s00213-014-3773-1 · DOI
- Fountoulakis, 2010, An update of evidence-based treatment of bipolar depression: where do we stand?, Curr Opin Psychiatry, 23, 19, 10.1097/YCO.0b013e328333e132 · DOI
- Fountoulakis, 2012, Refractoriness in bipolar disorder: definitions and evidence-based treatment, CNS Neurosci Ther, 18, 227, 10.1111/j.1755-5949.2011.00259.x · DOI · Paper page
- Fountoulakis, 2007, A seven- year follow-up of an extremely refractory bipolar I patient, CNS Spectr, 12, 733, 10.1017/S109285290001539X · doi:10.1017/s109285290001539x
- Fountoulakis, 2008, Ultra short manic-like episodes after antidepressant augmentation with modafinil, Prog Neuropsychopharmacol Biol Psychiatry, 32, 891, 10.1016/j.pnpbp.2007.11.006 · DOI
- Fountoulakis, 2017, The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 2: review, grading of the evidence, and a precise algorithm, Int J Neuropsychopharmacol, 20, 121
- Fountoulakis, 2017, The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines, Int J Neuropsychopharmacol, 20, 180
- Fountoulakis, 2017, The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), part 4: unmet needs in the treatment of bipolar disorder and recommendations for future research, Int J Neuropsychopharmacol, 20, 196
- Fountoulakis, 2017, The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), part 1: background and methods of the development of guidelines, Int J Neuropsychopharmacol, 20, 98
- Fountoulakis, 2012, Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry, Eur Arch Psychiatry Clin Neurosci, 262, 1, 10.1007/s00406-012-0323-x · DOI
- Fountoulakis, 2015, Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy, Int J Psychiatry Clin Pract, 19, 158, 10.3109/13651501.2014.1000930 · DOI
- Frangou, 2007, Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder, J Psychopharmacol, 21, 435, 10.1177/0269881106067787 · DOI
- Fries, 2012, Staging and neuroprogression in bipolar disorder, Curr Psychiatry Rep, 14, 667, 10.1007/s11920-012-0319-2 · DOI
- Frye, 2007, A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression, Am J Psychiatry, 164, 1242, 10.1176/appi.ajp.2007.06060981 · DOI · Paper page
- Gabriel, 2007, Adjunctive topiramate treatment in refractory obese bipolar patients: a descriptive open label study, Eat Weight Disord, 12, 48, 10.1007/BF03327772 · DOI
- Gajwani, 2009, Treatment-refractory bipolar disorder: classification to aid in clinical management, Expert Opin Pharmacother, 10, 1907, 10.1517/14656560903064170 · DOI
- Galling, 2015, Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis, Expert Opin Drug Saf, 14, 1181, 10.1517/14740338.2015.1053457 · DOI
- Geddes, 2002, BALANCE: a large simple trial of maintenance treatment for bipolar disorder, World Psychiatry, 1, 48
- Geddes, 2016, Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial, Lancet Psychiatry, 3, 31, 10.1016/S2215-0366(15)00450-2 · DOI · Paper page
- Ghaemi, 2004, Strategies for preventing the recurrence of bipolar disorder, J Clin Psychiatry, 65 (Suppl 10), 16
- Ghanizadeh, 2014, Lovastatin as an adjuvant to lithium for treating manic phase of bipolar disorder: a 4-week, randomized, double-blind, placebo-controlled clinical trial, Depress Res Treat, 2014, 730505
- Gijsman, 2004, Antidepressants for bipolar depression: a systematic review of randomized, controlled trials, Am J Psychiatry, 161, 1537, 10.1176/appi.ajp.161.9.1537 · DOI · Paper page
- Gitlin, 2006, Treatment-resistant bipolar disorder, Mol Psychiatry, 11, 227, 10.1038/sj.mp.4001793 · DOI · Paper page
- Gitlin, 2001, Treatment-resistant bipolar disorder, Bull Menninger Clin, 65, 26, 10.1521/bumc.65.1.26.18709 · DOI
- Goldberg, 2004, Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression, Am J Psychiatry, 161, 564, 10.1176/appi.ajp.161.3.564 · DOI · Paper page
- González-Isasi, 2010, Long-term efficacy of a psychological intervention program for patients with refractory bipolar disorder: a pilot study, Psychiatry Res, 176, 161, 10.1016/j.psychres.2008.06.047 · DOI
- González-Isasi, 2012, Predictors of good outcome in patients with refractory bipolar disorder after a drug or a drug and cognitive-behavioral treatment, Compr Psychiatry, 53, 224, 10.1016/j.comppsych.2011.05.001 · DOI
- González Isasi, 2014, Psychoeducation and cognitive-behavioral therapy for patients with refractory bipolar disorder: a 5-year controlled clinical trial, Eur Psychiatry, 29, 134, 10.1016/j.eurpsy.2012.11.002 · DOI · Paper page
- Green, 2000, Clozapine in the treatment of refractory psychotic mania, Am J Psychiatry, 157, 982, 10.1176/appi.ajp.157.6.982 · DOI
- Harel, 2011, H-coil repetitive transcranial magnetic stimulation for the treatment of bipolar depression: an add-on, safety and feasibility study, World J Biol Psychiatry, 12, 119, 10.3109/15622975.2010.510893 · DOI · Paper page
- Harvey, 2015, Treating insomnia improves mood state, sleep, and functioning in bipolar disorder: a pilot randomized controlled trial, J Consult Clin Psychol, 83, 564, 10.1037/a0038655 · DOI · Paper page
- Hidalgo-Mazzei, 2019, Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition, Br J Psychiatry, 214, 27, 10.1192/bjp.2018.257 · DOI
- Houston, 2006, Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex, J Clin Psychiatry, 67, 1246, 10.4088/JCP.v67n0811 · DOI
- Houston, 2009, Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study, J Clin Psychiatry, 70, 1540, 10.4088/JCP.08m04895yel · DOI
- Hui Poon, 2015, Pharmacological approaches for treatment-resistant bipolar disorder, Curr Neuropharmacol, 13, 592, 10.2174/1570159X13666150630171954 · DOI
- Investigators B, collaborators, 2010, Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial, Lancet, 375, 385, 10.1016/S0140-6736(09)61828-6 · DOI · Paper page
- Ionescu, 2015, A single infusion of ketamine improves depression scores in patients with anxious bipolar depression, Bipolar Disord, 17, 438, 10.1111/bdi.12277 · DOI
- Isasi, 2010, How effective is a psychological intervention program for patients with refractory bipolar disorder? A randomized controlled trial, J Affect Disord, 126, 80, 10.1016/j.jad.2010.03.026 · DOI
- Jahangard, 2014, In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder, Eur Neuropsychopharmacol, 24, 1210, 10.1016/j.euroneuro.2014.05.013 · DOI
- Juruena, 2009, Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial, Prog Neuropsychopharmacol Biol Psychiatry, 33, 94, 10.1016/j.pnpbp.2008.10.012 · DOI
- Kagawa, 2014, Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder, Ther Drug Monit, 36, 730, 10.1097/FTD.0000000000000088 · DOI
- Keck, 2001, Definition, evaluation, and management of treatment refractory mania, Psychopharmacol Bull, 35, 130
- Keller, 1992, Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium, Arch Gen Psychiatry, 49, 371, 10.1001/archpsyc.1992.01820050035005 · DOI · Paper page
- Kessing, 2016, Nationwide and population-based prescription patterns in bipolar disorder, Bipolar Disord, 18, 174, 10.1111/bdi.12371 · DOI
- Kessler, 2013, Neurocognitive profiles in treatment-resistant bipolar I and bipolar II disorder depression, BMC Psychiatry, 13, 105, 10.1186/1471-244X-13-105 · DOI
- Ketter, 2006, Adjunctive aripiprazole in treatment-resistant bipolar depression, Ann Clin Psychiatry, 18, 169, 10.1080/10401230600801176 · DOI · Paper page
- Ketter, 2015, Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder, J Affect Disord, 181, 87, 10.1016/j.jad.2015.04.012 · DOI
- Kimmel, 1994, Clozapine in treatment-refractory mood disorders, J Clin Psychiatry, 55, 91
- Koukopoulos, 1995, The long term prophylaxis of affective disorders, Adv Biochem Psychopharmacol, 49, 127
- Koukopoulos, 2010, Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder, Bipolar Disord, 12, 348, 10.1111/j.1399-5618.2010.00803.x · DOI
- Kramlinger, 1989, Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment-resistant mania, Acta Psychiatr Scand, 79, 378, 10.1111/j.1600-0447.1989.tb10273.x · DOI
- Kraus, 2017, Administration of ketamine for unipolar and bipolar depression, Int J Psychiatry Clin Pract, 21, 2, 10.1080/13651501.2016.1254802 · DOI
- Kusumakar, 1997, An open study of lamotrigine in refractory bipolar depression, Psychiatry Res, 72, 145, 10.1016/S0165-1781(97)00082-6 · DOI
- Lally, 2014, Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression, Transl Psychiatry, 4, e469, 10.1038/tp.2014.105 · DOI · Paper page
- Lattanzi, 2002, Pramipexole in treatment-resistant depression: a 16-week naturalistic study, Bipolar Disord, 4, 307, 10.1034/j.1399-5618.2002.01171.x · DOI · Paper page
- Lee, 2014, The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial, J Clin Psychopharmacol, 34, 337, 10.1097/JCP.0000000000000109 · DOI
- Lee, 2014, Genotype variant associated with add-on memantine in bipolar II disorder, Int J Neuropsychopharmacol, 17, 189, 10.1017/S1461145713000825 · DOI
- Li, 2015, Clozapine for treatment-resistant bipolar disorder: a systematic review, Bipolar Disord, 17, 235, 10.1111/bdi.12272 · DOI
- Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, Bmj, 339, b2700, 10.1136/bmj.b2700 · DOI · Paper page
- Lipsman, 2010, Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets, Bipolar Disord, 12, 691, 10.1111/j.1399-5618.2010.00868.x · DOI
- Liu, 2017, Efficacy and safety of long-term antidepressant treatment for bipolar disorders - A meta-analysis of randomized controlled trials, J Affect Disord, 223, 41, 10.1016/j.jad.2017.07.023 · DOI
- Lobban, 2010, Enhanced relapse prevention for bipolar disorder by community mental health teams: cluster feasibility randomised trial, Br J Psychiatry, 196, 59, 10.1192/bjp.bp.109.065524 · DOI · Paper page
- Loebel, 2014, Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study, Am J Psychiatry, 171, 169, 10.1176/appi.ajp.2013.13070985 · DOI · Paper page
- Loo, 2011, Physical treatments for bipolar disorder: a review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques, J Affect Disord, 132, 1, 10.1016/j.jad.2010.08.017 · DOI
- van der Loos, 2009, Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial, J Clin Psychiatry, 70, 223, 10.4088/JCP.08m04152 · DOI · Paper page
- van der Loos, 2010, Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine, Acta Psychiatr Scand, 122, 246, 10.1111/j.1600-0447.2009.01537.x · DOI
- van der Loos, 2011, Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design, Bipolar Disord, 13, 111, 10.1111/j.1399-5618.2011.00887.x · DOI
- Lykouras, 2004, Adjunctive topiramate in the maintenance treatment of bipolar disorders: an open-label study, Curr Med Res Opin, 20, 843, 10.1185/030079904125003665 · DOI
- Macfadden, 2009, A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently, Bipolar Disord, 11, 827, 10.1111/j.1399-5618.2009.00761.x · DOI · Paper page
- Machado-Vieira, 2008, A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania, J Clin Psychiatry, 69, 1237, 10.4088/JCP.v69n0806 · DOI · Paper page
- Magalhaes, 2011, N-acetylcysteine for major depressive episodes in bipolar disorder, Braz J Psychiatry, 33, 374, 10.1590/S1516-44462011000400011 · DOI
- Magalhaes, 2011, N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebocontrolled trial, J Affect Disord, 129, 317, 10.1016/j.jad.2010.08.001 · DOI
- Mahableshwarkar, 2017, Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: a phase 3, randomized controlled trial, J Affect Disord, 221, 275, 10.1016/j.jad.2017.06.044 · DOI
- Maj, 1995, Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors, Am J Psychiatry, 152, 1810, 10.1176/ajp.152.12.1810 · DOI · Paper page
- Manning, 2005, Burden of illness in bipolar depression, Prim Care Companion J Clin Psychiatry, 7, 259, 10.4088/PCC.v07n0601 · DOI
- Marangell, 2008, A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder, J Clin Psychiatry, 69, 183, 10.4088/JCP.v69n0203 · DOI
- Marcus, 2011, Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study, Bipolar Disord, 13, 133, 10.1111/j.1399-5618.2011.00898.x · DOI
- van der Markt, 2019, Testing a clinical staging model for bipolar disorder using longitudinal life chart data, Bipolar Disord, 21, 228, 10.1111/bdi.12727 · DOI
- McElroy, 1991, Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia, J Clin Psychiatry, 52, 411
- McElroy, 1997, A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder, Ann Clin Psychiatry, 9, 99, 10.3109/10401239709147781 · DOI
- McElroy, 1998, Olanzapine in treatment-resistant bipolar disorder, J Affect Disord, 49, 119, 10.1016/S0165-0327(98)00002-0 · DOI
- McElroy, 2000, Open-label adjunctive topiramate in the treatment of bipolar disorders, Biol Psychiatry, 47, 1025, 10.1016/S0006-3223(99)00316-9 · DOI · Paper page
- McElroy, 2011, A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance, Int Clin Psychopharmacol, 26, 48, 10.1097/YIC.0b013e3283400d35 · DOI
- McElroy, 2015, Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial, Int Clin Psychopharmacol, 30, 6, 10.1097/YIC.0000000000000051 · DOI
- Medda, 2009, Response to ECT in bipolar I, bipolar II and unipolar depression, J Affect Disord, 118, 55, 10.1016/j.jad.2009.01.014 · DOI
- Medda, 2010, Comparative response to electroconvulsive therapy in medication-resistant bipolar I patients with depression and mixed state, J Ect, 26, 82, 10.1097/YCT.0b013e3181b00f1e · DOI
- Medda, 2015, Electroconvulsive therapy in 197 patients with a severe, drug-resistant bipolar mixed state: treatment outcome and predictors of response, J Clin Psychiatry, 76, 1168, 10.4088/JCP.14m09181 · DOI
- Mendlewicz, 2010, Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study, Int Clin Psychopharmacol, 25, 297, 10.1097/YIC.0b013e32833c4ceb · DOI
- Meyer, 2012, Cognitive behaviour therapy and supportive therapy for bipolar disorders: relapse rates for treatment period and 2-year follow-up, Psychol Med, 42, 1429, 10.1017/S0033291711002522 · DOI · Paper page
- Miller, 1991, Prediction of treatment response in bipolar, manic disorder, J Affect Disord, 21, 75, 10.1016/0165-0327(91)90052-T · doi:10.1016/0165-0327(91)90052-t
- Mishory, 2000, Phenytoin as an antimanic anticonvulsant: a controlled study, Am J Psychiatry, 157, 463, 10.1176/appi.ajp.157.3.463 · DOI
- Mishory, 2003, Prophylactic effect of phenytoin in bipolar disorder: a controlled study, Bipolar Disord, 5, 464, 10.1046/j.1399-5618.2003.00070.x · DOI
- Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Bmj, 339, b2535, 10.1136/bmj.b2535 · DOI · Paper page
- Mukai, 2014, A meta-analysis of inositol for depression and anxiety disorders, Hum Psychopharmacol, 29, 55, 10.1002/hup.2369 · DOI · Paper page
- Mukherjee, 1988, Unilateral ECT in the treatment of manic episodes, Convuls Ther, 4, 74
- Murphy, 2012, Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial, J Clin Psychopharmacol, 32, 699, 10.1097/JCP.0b013e318266854c · DOI
- Murphy, 2014, Oral SAMe in persistent treatment-refractory bipolar depression: a double-blind, randomized clinical trial, J Clin Psychopharmacol, 34, 413, 10.1097/JCP.0000000000000064 · DOI
- Murray, 1994, Lithium maintenance therapy for bipolar I patients: possible refractoriness to reinstitution after discontinuation, Psychol Rep, 74, 355, 10.2466/pr0.1994.74.2.355 · DOI
- Nemeroff, 2001, Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression, Am J Psychiatry, 158, 906, 10.1176/appi.ajp.158.6.906 · DOI · Paper page
- Nierenberg, 2006, Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone, Am J Psychiatry, 163, 210, 10.1176/appi.ajp.163.2.210 · DOI · Paper page
- Nivoli, 2011, Gender differences in a cohort study of 604 bipolar patients: the role of predominant polarity, J Affect Disord, 133, 443, 10.1016/j.jad.2011.04.055 · DOI · Paper page
- Norris, 2013, A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder, J Affect Disord, 144, 141, 10.1016/j.jad.2012.06.023 · DOI
- Nuñez, 2018, Psychopathological and sociodemographic features in treatment-resistant unipolar depression versus bipolar depression: a comparative study, BMC Psychiatry, 18, 68, 10.1186/s12888-018-1641-y · DOI
- Obrocea, 2002, Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders, Biol Psychiatry, 51, 253, 10.1016/S0006-3223(01)01206-9 · DOI
- Ostacher, 2014, When positive isn’t positive: the hopes and disappointments of clinical trials, J Clin Psychiatry, 75, e1186, 10.4088/JCP.14com09427 · DOI
- Pacchiarotti, 2009, Treatment-resistant bipolar depression: towards a new definition, Acta Psychiatr Scand, 120, 429, 10.1111/j.1600-0447.2009.01471.x · DOI
- Pae, 2012, Achieving and sustaining remission in bipolar I disorder with ziprasidone: a post hoc analysis of a 24-week, double-blind, placebo-controlled study, Clin Drug Investig, 32, 747, 10.1007/s40261-012-0009-1 · DOI
- Pallanti, 2014, rTMS in resistant mixed states: an exploratory study, J Affect Disord, 157, 66, 10.1016/j.jad.2013.12.024 · DOI
- Pande, 2000, Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group, Bipolar Disord, 2, 249, 10.1034/j.1399-5618.2000.20305.x · DOI · Paper page
- Parikh, 2010, Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), Can J Psychiatry, 55, 136, 10.1177/070674371005500304 · DOI
- Parker, 2017, Clinical characteristics associated with treatment-resistant bipolar disorder, J Nerv Ment Dis, 205, 188, 10.1097/NMD.0000000000000517 · DOI
- Parsaik, 2015, Efficacy of ketamine in bipolar depression: systematic review and meta-analysis, J Psychiatr Pract, 21, 427, 10.1097/PRA.0000000000000106 · DOI
- Passos, 2017, Should bipolar disorder treatment be modified depending on staging?, Expert Rev Neurother, 17, 93, 10.1080/14737175.2017.1268532 · DOI
- Patkar, 2015, A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder, J Clin Psychopharmacol, 35, 319, 10.1097/JCP.0000000000000323 · DOI
- Pazzaglia, 1993, Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation, Psychiatry Res, 49, 257, 10.1016/0165-1781(93)90066-P · DOI
- Pazzaglia, 1998, Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness, J Clin Psychopharmacol, 18, 404, 10.1097/00004714-199810000-00009 · DOI
- Perry, 1999, Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment, Bmj, 318, 149, 10.1136/bmj.318.7177.149 · DOI · Paper page
- Perugi, 1999, Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states, Pharmacopsychiatry, 32, 136, 10.1055/s-2007-979219 · DOI · Paper page
- Perugi, 2012, Episode length and mixed features as predictors of ECT nonresponse in patients with medication-resistant major depression, Brain Stimul, 5, 18, 10.1016/j.brs.2011.02.003 · DOI
- Pilhatsch, 2010, Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study, J Affect Disord, 126, 453, 10.1016/j.jad.2010.04.025 · DOI
- Poleszczyk, 2018, Are there clinical and neurophysiologic predictive factors for a positive response to HF-rTMS in patients with treatment-resistant depression?, Psychiatry Res, 264, 175, 10.1016/j.psychres.2018.03.084 · DOI
- Poon, 2012, Evidence-based options for treatment-resistant adult bipolar disorder patients, Bipolar Disord, 14, 573, 10.1111/j.1399-5618.2012.01042.x · DOI
- Pope, 1991, Valproatereatment of Acute Mania, Arch Gen Psychiatry, 48, 62, 10.1001/archpsyc.1991.01810250064008 · DOI · Paper page
- Pope, 1991, Valproate in the treatment of acute mania. A placebo-controlled study, Arch Gen Psychiatry, 48, 62, 10.1001/archpsyc.1991.01810250064008 · DOI · Paper page
- Popovic, 2012, Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder, Eur Neuropsychopharmacol, 22, 339, 10.1016/j.euroneuro.2011.09.008 · DOI · Paper page
- Popovic, 2013, Polarity index of psychological interventions in maintenance treatment of bipolar disorder, Psychother Psychosom, 82, 292, 10.1159/000348447 · DOI · Paper page
- Popovic, 2014, Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study, Acta Psychiatr Scand, 129, 366, 10.1111/acps.12179 · DOI
- Post, 2012, Acquired lithium resistance revisited: discontinuation-induced refractoriness versus tolerance, J Affect Disord, 140, 6, 10.1016/j.jad.2011.09.021 · DOI
- Post, 2005, Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder, J Clin Psychiatry, 66, 370, 10.4088/JCP.v66n0314 · DOI
- Post, 2001, Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers, Bipolar Disord, 3, 259, 10.1034/j.1399-5618.2001.30505.x · doi:10.1034/j.1399-5618.2001.30505.x
- Post, 2008, Loss of previous responsiveness to lithium following its discontinuation and subsequent episode recurrence, 123
- Post, 1992, Lithium-discontinuation-induced refractoriness: preliminary observations, Am J Psychiatry, 149, 1727, 10.1176/ajp.149.12.1727 · DOI · Paper page
- Post, 1993, Lithium tolerance and discontinuation as pathways to refractoriness, 71
- Potter, 1982, Clorgyline. A new treatment for patients with refractory rapid-cycling disorder, Arch Gen Psychiatry, 39, 505, 10.1001/archpsyc.1982.04290050001001 · DOI
- Quante, 2010, Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study, Hum Psychopharmacol, 25, 126, 10.1002/hup.1096 · DOI
200 of 282 shown
Cited by
Carvalho, A. F., Firth, J., & Vieta, E. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1906193 · Cited by 562
Self-citationFountoulakis, K. N., Tohen, M., & Zarate, C. A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.003 · Cited by 146
Self-citationFernández‐Aranda, F., Treasure, J., Paslakis, G., Agüera, Z., Giménez, M., Granero, R., Sánchez, I., Serrano‐Troncoso, E., Gorwood, P., Herpertz‐Dahlmann, B., et al. (2021) · European Eating Disorders Review · doi:10.1002/erv.2822 · Cited by 99
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Self-citationSurjan, J., Grossi, J. D., Del Porto, J. A., Delfino, R. S., de Oliveira Cerqueira, R., Lucchese, A. C., Magalhães, E., Del Sant, L. C., Tuena, M. A., Nakahira, C., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01193-z · Cited by 19
Metadata
- Authors
- Fountoulakis, K. N., Yatham, L. N., Grunze, H., Vieta, E., Young, A. H., Blier, P., Tohen, M., Kasper, S., & Moeller, H. J.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-12-05
- Volume
- 23
- Issue
- 4
- Pages
- 230-256
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2992518829
- Cited by
- 77
- References
- 68
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. https://app.cochat.ai/papers/10.1093/ijnp/pyz064
- The paper
- Fountoulakis, K. N., Yatham, L. N., Grunze, H., Vieta, E., Young, A. H., Blier, P., Tohen, M., Kasper, S., & Moeller, H. J. (2020). The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyz064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.